This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Increased Serum Procollagen type I C-terminal Propeptide Levels are Associated with Left Ventricular Dysfunction in Patients Treated with Anthracycline-based Cancer Chemotherapy
Susana Ravassa
CIMA Universidad de Navarra
Corresponding Author
ORCiD: https://orcid.org/0000-0001-5926-5677
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Anthracycline-based cancer chemotherapy (ACC) has been related to myocardial interstitial fibrosis (MIF), a lesion contributing to left ventricular dysfunction (LVD). We investigated whether biomarker-assessed MIF was associated with LVD in patients with breast cancer receiving ACC and in patients with ACC-induced heart failure (ACC-HF). Moreover, chemotherapy agent’s pro-fibrotic activity was evaluated in human cardiac fibroblasts (HCFs).
Methods Echocardiography, serum biomarkers of collagen deposition (procollagen type-I C-terminal-propeptide [PICP]) and crosslinking (collagen type-I C-terminal-telopeptide/matrix metalloproteinase-1 ratio), and biomarkers of myocardial and vascular stress (galectin-3, sST2, amino-terminal pro-brain natriuretic peptide [NT-proBNP], hs-troponin-T and vascular cell adhesion molecule-1 [VCAM-1]) were assessed in 70 breast cancer patients at baseline, and during ACC at 3 and 6 months. Subclinical cardiotoxicity was defined as a global longitudinal strain (GLS) relative reduction>15%. In addition, PICP and NT-proBNP were determined in 347 patients with different HF etiologies, 37 with ACC-HF of whom 33 had 12-month-follow-up LVEF assessment. HCF activation was examined after incubation with chemotherapy agents for 24 hours.
Results In breast cancer patients, six-months-ACC reduced GLS and upregulated PICP, hs-troponin-T, NT-proBNP and VCAM-1 (P<0.01) versus baseline. At 6 months, elevation of PICP was higher in patients with subclinical cardiotoxicity versus the remaining patients (P for interaction<0.001). PICP levels were directly associated with a relative reduction in GLS (P<0.001). In ACC-HF patients, baseline LVEF was inversely associated with PICP and NT-proBNP (P<0.01). After 12 months, LVEF did not change in patients with higher basal PICP (3rd tertile) but improved in the remaining patients (P<0.001). Doxorubicin, cyclophosphamide and trastuzumab stimulated collagen synthesis in HCFs, including PICP extracellular cleavage.
Conclusion These results indicate that increased levels of PICP, a biomarker related to MIF, are associated with early LVD in ACC-treated patients with breast cancer and with established LVD in ACC-HF patients, hindering LV functional improvement after 12 months. Chemotherapy can directly activate collagen metabolism and increase PICP extracellular presence in HCFs. Therefore, PICP emerges as a promising biomarker of ACC-induced cardiotoxicity.
Keywords
Anthracycline-based chemotherapy, myocardial fibrosis, biomarkers, cardiotoxicity, global longitudinal strain, left ventricular ejection fraction
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
- CardiotoxMFSuppl9Dic20.docx
Additional file 1 includes table S1. Longitudinal changes in biochemical and echocardiographic parameters, and in biomarkers, in patients with breast cancer. Table S2. Univariable linear mixed model analyses among biomarkers (log2) and echocardiographic parameters in patients with breast cancer. Table S3. Univariable logistic regression analyses for the association between biomarker levels and subclinical cardiotoxicity at visit 2 in patients with breast cancer. Table S4. Fold change variations in human cardiac fibroblasts with respect to control conditions.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 22 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Increased Serum Procollagen type I C-terminal Propeptide Levels are Associated with Left Ventricular Dysfunction in Patients Treated with Anthracycline-based Cancer Chemotherapy
Susana Ravassa
CIMA Universidad de Navarra
Corresponding Author
ORCiD: https://orcid.org/0000-0001-5926-5677
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 22 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Anthracycline-based cancer chemotherapy (ACC) has been related to myocardial interstitial fibrosis (MIF), a lesion contributing to left ventricular dysfunction (LVD). We investigated whether biomarker-assessed MIF was associated with LVD in patients with breast cancer receiving ACC and in patients with ACC-induced heart failure (ACC-HF). Moreover, chemotherapy agent’s pro-fibrotic activity was evaluated in human cardiac fibroblasts (HCFs).
Methods Echocardiography, serum biomarkers of collagen deposition (procollagen type-I C-terminal-propeptide [PICP]) and crosslinking (collagen type-I C-terminal-telopeptide/matrix metalloproteinase-1 ratio), and biomarkers of myocardial and vascular stress (galectin-3, sST2, amino-terminal pro-brain natriuretic peptide [NT-proBNP], hs-troponin-T and vascular cell adhesion molecule-1 [VCAM-1]) were assessed in 70 breast cancer patients at baseline, and during ACC at 3 and 6 months. Subclinical cardiotoxicity was defined as a global longitudinal strain (GLS) relative reduction>15%. In addition, PICP and NT-proBNP were determined in 347 patients with different HF etiologies, 37 with ACC-HF of whom 33 had 12-month-follow-up LVEF assessment. HCF activation was examined after incubation with chemotherapy agents for 24 hours.
Results In breast cancer patients, six-months-ACC reduced GLS and upregulated PICP, hs-troponin-T, NT-proBNP and VCAM-1 (P<0.01) versus baseline. At 6 months, elevation of PICP was higher in patients with subclinical cardiotoxicity versus the remaining patients (P for interaction<0.001). PICP levels were directly associated with a relative reduction in GLS (P<0.001). In ACC-HF patients, baseline LVEF was inversely associated with PICP and NT-proBNP (P<0.01). After 12 months, LVEF did not change in patients with higher basal PICP (3rd tertile) but improved in the remaining patients (P<0.001). Doxorubicin, cyclophosphamide and trastuzumab stimulated collagen synthesis in HCFs, including PICP extracellular cleavage.
Conclusion These results indicate that increased levels of PICP, a biomarker related to MIF, are associated with early LVD in ACC-treated patients with breast cancer and with established LVD in ACC-HF patients, hindering LV functional improvement after 12 months. Chemotherapy can directly activate collagen metabolism and increase PICP extracellular presence in HCFs. Therefore, PICP emerges as a promising biomarker of ACC-induced cardiotoxicity.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6